Day: September 30, 2024

//NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES// VANCOUVER, British Columbia, Sept. 30, 2024 (GLOBE NEWSWIRE) — Refined Energy Corp. (CSE: RUU; FRA: CWA0) (the “Company”) is pleased to announce the closing of its previously announced non-brokered private placement offering (“Offering”) of units of the Company (“Units”) with the issuance of 1,750,000 Units at a price of $0.20 per Unit for gross proceeds of $350,000. Each Unit consists of one common share of the Company (a “Common Share”) and one Common Share purchase warrant (a “Warrant”), whereby each Warrant entitles the holder to acquire one Common Share at a price of $0.25 for a period of 24 months from the date of issuance. Proceeds of the Offering will be used to finance exploration activities on the Company’s projects and...

Patient Special Access Program continues during Health Canada review MELBOURNE, Australia, Oct. 01, 2024 (GLOBE NEWSWIRE) — CLINUVEL has filed a New Drug Submission (NDS) to Health Canada, seeking approval for its novel photoprotective therapy SCENESSE® (afamelanotide) for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). If approved, SCENESSE® would be the first treatment for Canadian EPP patients. Health Canada review process Health Canada’s Health Products and Food Branch (HPFB) reviews and approves medications for use in Canada, assessing the safety and efficacy of the products in the proposed indication, as well as the drug’s quality. Following a formal dossier validation period, the HPFB may complete the review of a new drug candidate within 300 days. Canadian Special Access Program...

BETHESDA, Md., Sept. 30, 2024 (GLOBE NEWSWIRE) — Eagle Bancorp, Inc. (NASDAQ: EGBN), the Bethesda-based holding company for EagleBank, one of the largest community banks in the Washington D.C. area, today announced two actions taken to position itself for future growth. As of September 30, 2024, the Company closed on a private placement of a five-year senior debt totaling $77.7 million maturing on September 30, 2029, and recalibrated its cash dividend for the third quarter of 2024 to reflect the company’s growth plans. “At EagleBank, our highest priorities are advancing our growth strategy and expanding the diversity of our deposit and loan portfolio.” said Susan G. Riel, Eagle Bancorp President and Chief Executive Officer. “This successful transaction boosts our ability to pursue sustained growth and demonstrates the confidence...

SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the publication of its KOMET-001 Phase 1 study manuscript in The Lancet Oncology journal. The paper, entitled “Ziftomenib in relapsed/refractory acute myeloid leukaemia (KOMET-001): results from an open-label, multi-cohort, phase 1a/1b trial,” is now available on The Lancet Oncology website and in the Scientific Manuscripts section on Kura’s website. “The results from the KOMET-001 Phase 1 study are encouraging as they demonstrate meaningful benefit of ziftomenib in NPM1-mutant acute myeloid leukemia (AML), and publication of these data expands the growing evidence supporting the efficacy and safety of ziftomenib...

TORONTO, Ontario, Sept. 30, 2024 (GLOBE NEWSWIRE) — Titan Medical Inc. (“Titan”) (TSX: TMD; OTC: TMDIF) announced the voting results from its Annual General and Special Meeting of Shareholders (the “AGM”) held virtually via live audio webcast on September 30, 2024. Shareholders voted in favour of all management resolutions proposed in Titan’s management information circular dated August 30, 2024 (the “Circular”). Resolutions proposed and approved at the AGM include: fixing the number of directors and election of directors of Titan for the ensuing year (“Director Resolution”); appointing MNP LLP as auditors of Titan for the ensuing year and authorizing the directors to fix the remuneration of the auditors (“Auditor Resolution”); subject to the completion of the Transaction (as defined herein), the change of name of Titan to “Conavi...

SINGAPORE, Sept. 30, 2024 (GLOBE NEWSWIRE) — HomesToLife Ltd. (“HTLM” or the “Company”) today announced the pricing of its initial public offering of an aggregate of 1,250,000 ordinary shares (the “Offering”), all of which are being offered by HTLM at a public offering price of $4.00 per share. In addition, the Company has granted the underwriters a 45-day option (the “Over-Allotment Option”) to purchase up to an additional 187,500 ordinary shares at the initial public offering price, less underwriting discounts and commissions. The gross proceeds to HTLM from the Offering (assuming that the Over-Allotment Option is not exercised), before deducting underwriting discounts and commissions and estimated offering expenses payable by HTLM, is expected to be $5 million. The shares are expected to begin trading on the Nasdaq Capital...

CALGARY, Alberta, Sept. 30, 2024 (GLOBE NEWSWIRE) — Prairie Provident Resources Inc. (“Prairie Provident” or the “Company”) (TSX:PPR) is pleased to announce the closing of the initial $10.0 million subscription by its principal shareholder, PCEP Canadian Holdco, LLC (“PCEP”), under the Company’s previously-announced $13.2 million rights offering (the “Rights Offering”). Up to 529,579,000 common shares of Prairie Provident (“Common Shares”) are issuable under the Rights Offering at a subscription price of $0.025 per share, for an aggregate subscription price, if fully subscribed, of $13,239,475. The $10.0 million subscription by PCEP represents its pro rata share (approximately 75.5%) of the Rights Offering, and resulted in PCEP acquiring an additional 400,000,000...

TORONTO, Sept. 30, 2024 (GLOBE NEWSWIRE) — Dundee Corporation (TSX: DC.A) (the “Company” or “Dundee”) announced today that, in alignment with its commitment to its core strategic objectives, it has entered into a definitive agreement to sell its investment management business (the “Investment Management Business”) operated through Goodman & Company, Investment Counsel Inc. to Next Edge Capital Corp. (“Next Edge”) (the “Transaction”). The decision to sell the Investment Management Business enables the Company to enhance its focus on its core investment strategy while streamlining operations and further rationalizing its cost structure. Lila Manassa Murphy, Executive Vice President and Chief Financial Officer of Dundee, commented: “This transaction represents a significant strategic step toward cost rationalization, allowing...